James A. Schoeneck
Independent Chairman of the BoardMr. James A. Schoeneck, also known as Jim, is Independent Director of Connect Biopharma Holdings Limited from July 22, 2025. Mr. Schoeneck is an Independent Chairman of the Board at Kyntra Bio, Inc. (formerly known as FibroGen, Inc.) since January 6, 2020 and was its Interim President until February 14, 2020. He served as Interim Chief Executive Officer of Kyntra Bio, Inc. (formerly known as FibroGen, Inc.) from January 2019 to February 2020. Mr. Schoeneck serves as a Strategic Advisor to Kreido Laboratories. Mr. Schoeneck served as the President of DepoMed, Inc. from April 18, 2014 to March 28, 2017 and Chief Executive Officer from 2011 until 2017. He serves as an Independent Director at Calidi Biotherapeutics, Inc. since July 2020 and serves as its Chairman of the Board since April 22, 2025. He served as the Chief Executive Officer of BrainCells Inc. from October 2005 to 2011. Mr. Schoeneck served as Chief Executive Officer of ActivX Biosciences Inc., from November 2003 to December 2004. Mr. Schoeneck served as President and Chief Executive Officer of Prometheus Laboratories Inc. from 2000 to 2003 and previously served as its President and Chief Operating Officer. Mr. Schoeneck served as Vice President and General Manager, Immunology Business Unit at Centocor, Inc (now Janssen Biotech, Inc.). He served as Vice President of Marketing and Commercial Development at Johnson & Johnson subsidiary, Centocor, Inc. He negotiated and led Centocor's strategic Partnership with Schering-Plough for Remicade rights outside the U.S and worked with Lilly and GSK on other monoclonal antibody-based Partnerships. He spent years at Rhone-Poulenc Rorer, Inc. where he held multiple sales and marketing positions, including Director of Healthcare Services, Director of Marketing and various other positions. He has been a Director of Kyntra Bio, Inc. (formerly known as FibroGen, Inc.) since April 2010. He was a Director of AnaptysBio, Inc. from November 19, 2015 until March 19, 2018. He served as a Director of BrainCells, Inc. from October 2005 to 2007. He served as a Director of ActivX Biosciences, Inc. He served as a Director at DepoMed, Inc. from December 2007 to March 28, 2017. He served as Chairman of the Board at the Asthma and Allergy Foundation of America. Mr. Schoeneck served on the Board of Directors of BIOCOM and AAFA. Mr. Schoeneck holds a Bachelor of Science Degree in Education from Jacksonville State University.
Positions
- Company NameKyntra Bio, Inc.Stock CodeKYNBPositionIndependent Chairman of the BoardColleagues
- TWThane WettigCEO & Director
- JAJames A. SchoeneckIndependent Chairman of the Board
- DDDavid DeLuciaSenior VP & CFO
- JAJohn AldenCorporate Secretary & General Counsel
- MSMichelle SimonettiHead of People and Culture & Executive Director
- CBCarrie BrownsteinChief Medical Officer
- JLJeffrey L. EdwardsIndependent Director
- MGMichael Glen KauffmanIndependent Director
- AEAndrew E. SingerIndependent Director
- Company NameCalidi Biotherapeutics, Inc.Stock CodeCLDIPositionIndependent Chairman of the BoardRelated SecuritiesColleagues
- EEEric E. PomaCEO & Director
- ACAndrew C. JacksonCFO & Corporate Secretary
- AFAntonio Fernandez SantidrianHead of Technical Operations & Chief Scientific Officer
- GTGuy Travis CliftonChief Medical Officer
- SLScott LeftwichIndependent Vice-Chairman of the Board
- ARAlan R. StewartIndependent Director
- DZDmitriy ZamarinMember of Scientific Advisory Board
